医学
任天堂
特发性肺纤维化
头痛
内科学
酪氨酸激酶抑制剂
胃肠病学
外科
肺
癌症
作者
Robert Patejdl,S. Markmann,R. Benecke,Matthias Wittstock
标识
DOI:10.1016/j.clineuro.2013.01.011
摘要
Idiopathic pulmonary fibrosis (IPF) is a rare progressive interstitial lung disease characterized by declining lung function, worsening dyspnea and poor prognosis with median survival of 3–5 years. IPF predominantly affects people over 60 years, it however has worse prognosis in younger patients with genetic predisposition like short telomere syndrome. Nintedanib, one of two anti-fibrotic therapies approved for IPF treatment has occasional neurological side effects like fatigue, dizziness and headaches. Significant polyneuropathy or motor dysfunction is rarely seen. This case report illustrates a patient who developed quadriparesis following initiation of Nintedanib.
科研通智能强力驱动
Strongly Powered by AbleSci AI